Diabetes and renal transplantation : Saudi experience

Abstract EN

We conducted this study to evaluate the prevalence and risk factors of diabetes mellitus (DM) in our renal transplant population.

We retrospectively reviewed the records of the active renal transplant patients at two large transplant centers in Riyadh and Jeddah in Saudi Arabia, transplanted between 1979 and November 1998.

The recipients were grouped according to the diagnosis of diabetes ; group I : diabetes developed before transplantation (BTDM), group II : diabetes developed only after transplantation (ATDM) and group III : did not have diabetes (NDM).

There were 1112 patients' records included in the study.

The mean age was 38.2 years and the mean duration of transplantation was 66.9 months.

There were 113(10.2 %) patients in BTDM group, 134 (12.1 %) patients in the ATDM group and 865 (77.8 %) patients in the NDM group.

There was no significant difference in the prevalence of hypertension among the study groups.

In comparison to the other groups, the BTDM group had significantly more males (78.8 %), more patients who were transplanted after 1990 (pre-cyclosporin era), more patients with grafts from living non-related donors (46 %), higher incidence of acute rejection episodes (39 %), higher mean serum creatinine and more patients treated with azathioprine (71 %).

The ATDM group had significantly higher mean age (46.4 years), higher mean duration of transplantation (91.5 months), higher rate of retransplantation (8.2 %), higher mean serum cholesterol level (6.0mmol / L) and more frequently abnormal electrocardiogram (24.6 %) than the other two groups.

The ATDM group had comparable mean weight (70.2 kg) to the BTDM group but significantly higher than the NDM group (66.1kg).

The NDM group had significantly higher mean dose of cyclosporine (3.3 mg / kg / day) and higher mean dose of prednisone (0.16 mg / kg / day) than the other groups.

The only independent risk factor for developing DM after transplantation was advancing age.

The currently used low-dose steroid therapy was not significantly associated with development of DM after renal transplantation.

Nevertheless DM is an important co-morbid condition in the transplant population and is associated with increased risk for cardiovascular and cerebrovascular events.